An interventional study of Standard mixed breakfast meal and SmartBar™ in Healthy Participants, sponsored by Kristine Færch. Completed at 1 site in Denmark. Open to participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-18.
Sponsored by Kristine Færch · Not applicable, Interventional, and Treatment
The wireless motility capsule technology, SmartPill™, can be used to assess gastric emptying and gastrointestinal (GI) transit time. The SmartPill is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet. The primary aim of the present study is to compare effects of a SmartBar™ and a standard mixed meal on gastric emptying and GI motility.
Background: The wireless motility capsule technology, SmartPill™, can be used to assess GI transit time including gastric emptying and small and large bowel transit time based on measurements of pH, pressure and temperature. The SmartPill™ allows for GI motility measurements under free-living conditions without radiation. The SmartPill is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet. GI motility in response to meals plays an important role in regulation of e.g. appetite and glucose metabolism. Changes in appetite and metabolism in response to interventions are often assessed using a meal test and GI motility is assessed at the research facilities. The use of SmartPill™ in combination with a meal test would allow for assessment of GI motility under subsequent free-living conditions and improve our understanding of the effects of interventions on the integrative relationship between food intake, GI motility and metabolism. Most of our daily decisions and actions affecting energy intake are driven by the non-conscious processes; however, appetite is often assessed from participants' self-report which is associated with limitations such as desire to report socially desirable answers. Little is known about the complex interrelationship between biological markers of appetite e.g. GI hormones and subjective and objective measures of food related behavior under fasting and fed conditions.
The PRESET study has the following objectives:
Testing includes assessments in the fasting state and in response to consumption of the SmartBar™ and a standard mixed meal (4-hour meal tests and subsequent 6-days free-living assessment period) on two separate test days.
Kristine Færch is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The wireless capsule technology, SmartPill™, is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet.
Other: SmartBar™
The SmartPill™ is ingested together with a standard mixed breakfast meal and the outcomes of interest will be compared with the SmartBar™ condition (reference).
Other: Standard mixed breakfast meal
The standard mixed breakfast meal consists of: 150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate
SmarBar™ (Medtronic, North Haven, MA, USA). Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.
Gastric emptying time (minutes)
Measured by the SmartPill™ technique. The SmartPill™ is ingested at both visits in combination with the standard breakfast meal and SmartBar™, respectively. The time frame depends on the individual gastric emptying time.
Time frame: Within 24 hours from ingestion of the SmartPill™ at both visits (standard breakfast meal and SmartBar™, respectively)
Small bowel transit time (minutes)
Measured by the SmartPill™ technique. The SmartPill™ is ingested at both visits in combination with the standard breakfast meal and SmartBar™, respectively. The time frame depends on the individual transit time.
Time frame: Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
Large bowel transit time (minutes)
Measured by the SmartPill™ technique. The SmartPill™ is ingested at both visits in combination with the standard breakfast meal and SmartBar™, respectively. The time frame depends on the individual transit time.
Time frame: Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
Total gastrointestinal transit time (minutes)
Measured by the SmartPill™ technique. The SmartPill™ is ingested at both visits in combination with the standard breakfast meal and SmartBar™, respectively. The time frame depends on the individual transit time.
Time frame: Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
Motility index (arbitrary unit)
Calculated based on amplitudes and number of contractions measured using the SmartPill™ technique. The greater the motility index the greater the gastrointestinal motility (i.e. more frequent and stronger contractions). A higher motility index has been observed among healthy participants compared to patients with diabetic gastroparesis indicating that a higher index is favorable.
Time frame: Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
Metabolites
Concentrations of metabolites (including but not limited to: glucose, lipids, cholesterol, free-fatty acids, and amino acids. Measured at both visits in the fasting state and for 4 hours after consumption of the standard breakfast meal and the SmartBar™, respectively.
Time frame: 0 minutes (fasting) and 15, 30, 45, 60, 90, 120, 180, 240 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
Hormones
Concentrations of hormones related to regulation of appetite, glucose and lipid metabolism (including but not limited to: insulin, glucagon, ghrelin, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY), leptin, fibroblast growth factor 19 (FGF-19), fibroblast growth factor 21 (FGF-21), growth differentiation factor 15 (GDF-15)).
Time frame: 0 minutes (fasting) and 15, 30, 45, 60, 90, 120, 180, 240 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
Attention measured using eye tracking
Eye tracking metrics including gaze duration bias, gaze direction bias, fixations, saccades, pupil size/dilation, distance to screen, ocular vergence and blinks to measure attention in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire
Time frame: 0 minutes (fasting) at 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
Arousal measured using galvanic skin response
Changes in conductivity of skin (galvanic skin response) in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire
Time frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
Emotions measured using facial expression analysis
Facial expression analyses using computer-vision algorithms (AFFDEX) to measure emotions in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire
Time frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
Food choice
Food choice of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Food choice is determined based on frequency of selection made within each food category. The scores range from 0-48 i.e. 0 = foods within a specific food category have not been selected at all to 48 = foods within a specific food category have been selected 48 times.
Time frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
Implicit wanting
Implicit wanting of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Implicit wanting is assessed based on food choice and response time for selected and non-selected food items as well as mean response time.
Time frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
Explicit liking
Explicit liking of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Explicit liking is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how pleasant would it be to taste this food right now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale).
Time frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
Explicit wanting
Explicit wanting of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Explicit wanting is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how much do you want some of this food now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale).
Time frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
Subjective appetite
Rated using visual analogue scales and includes sensations of: Hunger, fullness, satiety, prospective food consumption, wellbeing, nausea, thirst, desire to eat meat, salty, and sweet. The scale range is 0-100 and each end represent the extremes e.g. hunger rating: "I am not hungry at all" to "I have never been this hungry before".
Time frame: 0 minutes (fasting) and 15, 30, 45, 60, 90, 120, 180, 240 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
Self-reported gastrointestinal symptoms (part 1)
Assessed from the questionnaire the Gastrointestinal Symptom Rating Scale (GSRS). Rated on 7-point likert scales. Range: 1 = absence of symptoms to 7 = very severe symptoms.
Time frame: Answered during test days (0-240 minutes)
Self-reported gastrointestinal symptoms (part 2)
Assessed from the Gastrointestinal Symptom Score (PAGI-SYM). Rated on 6-point likert scales. Range: 1 = absence of symptoms to 6 = very severe symptoms.
Time frame: Answered during test days (0-240 minutes)
Self-reported gastrointestinal symptoms (part 3)
Number of symptoms. Assessed from logs.
Time frame: Registered 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Self-reported autonomic symptoms
Assessed from the questionnaire COMPASS31
Time frame: Answered during test days (0-240 minutes)
Body weight (kg)
Body weight is measured on a digital scale
Time frame: At 0 minutes (fasting) at both visits
Body mass index (kg/m^2)
Calculated from body weight (kg) and height (m)
Time frame: At 0 minutes (fasting) at both visits
Fat mass (kg)
Measured by Dual-energy X-ray Absorptiometry
Time frame: At 0 minutes (fasting) at both visits
Fat percentage (%)
Measured by Dual-energy X-ray Absorptiometry
Time frame: At 0 minutes (fasting) at both visits
Fat free mass (kg)
Measured by Dual-energy X-ray Absorptiometry
Time frame: At 0 minutes (fasting) at both visits
Waist circumference (cm)
Measured using tape measure
Time frame: At 0 minutes (fasting) at both visits
Hip circumference (cm)
Measured using tape measure
Time frame: At 0 minutes (fasting) at both visits
Mean amplitude of glycaemic excursions (MAGE)
Measured using continous glucose monitoring
Time frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Continuous overall net glycaemic action (CONGA)
Measured using continous glucose monitoring
Time frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Daily time spent above different glucose concentrations (e.g. >6.1 mmol/L, >7.0 mmol/L, >7.8 mmol/L, and >11.1 mmol/L)
Measured using continous glucose monitoring
Time frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Mean glucose concentrations
Measured using continous glucose monitoring
Time frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Standard deviation of glucose concentrations
Measured using continous glucose monitoring
Time frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Variation coefficients of glucose concentrations
Measured using continous glucose monitoring
Time frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Resting energy expenditure (kcal/day)
Measured by indirect calorimetry under resting and fasting conditions
Time frame: At 0 minutes (fasting) at both visits
Substrate oxidation (respiratory exchange ratio)
Measured by indirect calorimetry under resting and fasting conditions
Time frame: At 0 minutes (fasting) at both visits
Systolic blood pressure (mmHg)
Measured under resting and fasting conditions
Time frame: At 0 minutes (fasting) at both visits
Diastolic blood pressure (mmHg)
Measured under resting and fasting conditions
Time frame: At 0 minutes (fasting) at both visits
Heart rate (bpm)
Measured under resting and fasting conditions during measurements of blood pressure and in the supine position by a handheld ECG measuring device (Vagus™).
Time frame: At 0 minutes (fasting) at both visits
Heart rate response to standing up from the supine position
Measured by a handheld ECG measuring device (Vagus™).
Time frame: At 0 minutes (fasting) at both visits
Heart rate response to inhalation and exhalation
Measured by a handheld ECG measuring device (Vagus™).
Time frame: At 0 minutes (fasting) at both visits
Heart rate response to forced exhalation during rest (valsalva maneuver)
Measured by a handheld ECG measuring device (Vagus™).
Time frame: At 0 minutes (fasting) at both visits
Microbiome content and diversity
Determined from stool samples. Bacterial DNA and RNA will be purified from the stool samples and changes in the microbiome composition and function will be estimated based on sequencing of the microbiomes' DNA and RNA. Includes but is not limited to the Firmicutes/Bacteroidetes ratio.
Time frame: One sample during 6 days after both visits
Physical activity (time spent at different intensities)
Sedentary time, light, moderate and vigorous intensity physical activity. Assessed from 24 h/day accelerometry
Time frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Physical activity (counts/min)
Assessed from 24 h/day accelerometry
Time frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Physical activity energy expenditure (kcal/day)
Assessed from 24 h/day accelerometry
Time frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Physical activity (MET hours)
Assessed from 24 h/day accelerometry
Time frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Timing of physical activity (hh:mm)
Assessed from activity logs and 24 h/day accelerometry
Time frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Energy intake (kcal/day)
Assessed from diet records
Time frame: Assessed for 3 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Macronutrient intake (energy percentage)
Assessed from diet records
Time frame: Assessed for 3 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Timing of dietary intake (hh:mm)
Assessed from diet records
Time frame: Assessed for 3 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Sleep timing (hh:mm)
Including bedtime, sleep onset, wake-up, time out of bed, sleep midpoint. Assessed from sleep logs and 24 h/day accelerometry
Time frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Sleep duration (minutes)
Assessed from sleep logs and 24 h/day accelerometry
Time frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Sleep variability (minutes)
Variability in bedtime, wake-up, sleep duration and sleep midpoint. Assessed from sleep logs and 24 h/day accelerometry
Time frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Sleep onset latency (minutes)
Assessed from sleep logs and 24 h/day accelerometry
Time frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Sleep efficiency (%)
Assessed from 24 h/day accelerometry
Time frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
Wakefulness (minutes)
Assessed from 24 h/day accelerometry
Time frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
HbA1c (mmol/mol and %)
Hemoglobin A1c
Time frame: At 0 minutes at both visits
Insulin sensitivity (indices)
Including but not limited to the Matsuda index
Time frame: At 0 minutes (fasting) and 4 hours after consumption of the standard breakfast meal and the SmartBar™, respectively
Insulin resistance (indices)
Including but not limited to Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Time frame: At 0 minutes (fasting) and 4 hours after consumption of the standard breakfast meal and the SmartBar™, respectively
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kristine Færch